Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD69 Double Nickase Plasmid (h): sc-416315-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD69 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD69 Double Nickase Plasmid (h) and CD69 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD69. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD69 Antibody (D-3): sc-373799
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD69 Double Nickase Plasmid (h) | sc-416315-NIC | 20 µg | $410.00 | |||
CD69 Double Nickase Plasmid (h2) | sc-416315-NIC-2 | 20 µg | $410.00 |
CD69 encodes an early activation antigen expressed on the surface of T cells, B cells, NK cells, and other leukocytes, where it functions as a C-type lectin receptor that rapidly marks immune activation. CD69 participates in signaling and cell–cell interaction programs that shape lymphocyte retention and migration, including modulation of sphingosine-1-phosphate receptor (S1PR1)-dependent egress and coordination of tissue residency. Through its impact on activation thresholds, cytokine responses, and immune synapse dynamics, CD69 is frequently studied in pathways governing inflammation, immune tolerance, and host defense. Altered CD69 expression patterns have been reported across immune-mediated diseases and cancer immunology contexts, supporting its use as a mechanistic marker and functional node in leukocyte biology studies.
CD69 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD69 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD69. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD69 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD69-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.